[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tyrosine-kinase-inhibitor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tyrosine-kinase-inhibitor":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,74,107,139,162,186],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100597642","a-potential-relationship-between-treatment-with-tyrosine-kinase-inhibitors-and-erectile-dysfunction-in-male-patients-with-chronic-myeloid-leukemia-100597642",false,"NCT07061145","A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia","ED2024","Inclusion Criteria:\n\n* Patients diagnosed with chronic phase Philadelphia chromosome-positive (Ph+) and\u002For BCR-ABL-positive CML.\n* Patients starting frontline treatment with TKIs between 01st January 2015 and 31st January 2022.\n* Age greater than or equal to 18 years and not exceeding 75 years at the time of starting therapy.\n* Male sex.\n* Exposure to Hydroxyurea or Anagrelide before the initiation of TKI therapy is allowed\n* Ability to provide informed consent, as demonstrated by a clear understanding of the study's objectives and procedures and the ability to make an informed and voluntary decision to participate\n* Signed written informed consent according to ICH\u002FEU\u002FGCP and national and local laws.\n\nExclusion Criteria:\n\n* Patients with advanced phases (accelerated or blastic phase) Ph+ and\u002For BCR-ABL+ CML\n* Patients who experienced ED before TKI initiation","MALE","18 Years","75 Years",{"count":20,"type":21},350,"ESTIMATED","OBSERVATIONAL","Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome, resulting in the constitutive activation of the BCR-ABL1 tyrosine kinase. The advent of tyrosine kinase inhibitors (TKIs) has revolutionized the management of CML, trasforming it from a fatal disease to a chronic condition with excellent long-term outcomes for the majority of patients. The introduction of tyrosine kinase inhibitor (TKI) based treatment for CML has revolutionized the management of this previously fatal disease, achieving sustained disease-control in more than 90% of patients.\n\nHowever, as patients with CML are often required to undergo lifelong TKI therapy to maintain disease control, concerns regarding the long-term safety and tolerability of these agents have emerged.\n\nThe efficacy of second and third-generation TKIs exceeds the efficacy of imatinib, owing to their potent impact on wild-type BCR-ABL1 and various BCR-ABL1 mutants, along with additional drug targets. Furthermore, TKIs exhibit activity on non-kinase targets (es. oxidoreductase NQO2 for nilotinib and imatinib).\n\nThe prolonged treatment duration and expanded TKIs repertoire have led the emergence of various unexpected non-hematologic adverse events (AE), notably vascular adverse events (VAEs).\n\nRecent evidence indicates a relatively high incidence of severe arterial changes in TKI-treated patients, with VAEs frequency correlating with TKI dosage and treatment duration. However, data elucidating the clinical features of vascular events are lacking.\n\nHormonal alterations have been reported in patients treated with imatinib. The tyrosine-kinase receptors cKIT and PDGF receptors, along with their respective ligands, are expressed in the testis, where they play a role in stimulating testosterone secretion by Leydig cells. Prolonged imatinib use has been associated with reduced testosterone production due to PDGFR and cKit blockade in the testis, potentially leading to gynaecomastia in men.\n\nCardiovascular disease (CVD) remains the leading cause of mortality in the United States, accounting for nearly 40% of all deaths. CVD and ED share a variety of common risk factors, including hypertension, diabetes, dyslipidemia, smoking, obesity, physical inactivity, and metabolic syndrome. Screening and diagnosing ED hold significant potential for secondary prevention of CVD. Despite the estabilished association between ED and CVD, the precise mechanisms driving ED's predictive value for CVD are yet to be fully identified. Early deection and treatment of CVD during the critical time frame in which risk factors can be modified will effectively reduce the occurrence of fatal CV events in male patients with ED.\n\nThis is a multicentre national, retrospective, prospective, non-interventional study that focuses on male CML patients starting first-line treatment with TKIs between 1 January 2015 and 31 January 2022.\n\nAll enrolled patients will be involved in both retrospective and prospective evaluations.\n\nThe retrospective component of the study allows the collection of data on the onset of ED, documented in medical records, that occurred before enrolment. It also includes information from physical examinations and laboratory tests, such as complete blood count, serum biochemistry (including renal and liver function tests, lipid profile and glycosylated haemoglobin), molecular biology for BCR-ABL transcript levels and electrocardiography (ECG), collected retrospectively every six months from enrolment until the documented onset of ED. The prospective evaluation assesses the occurrence of ED in the six months prior to enrolment and during the two-year follow-up period.\n\nThe primary objective of the study is to assess the incidence of erectile dysfunction (ED) among male patients with chronic myeloid leukaemia (CML) undergoing treatment with tyrosine kinase inhibitors (TKIs), imatinib, dasatinib, nilotinib, bosutinib or ponatinib, focusing in particular on those individuals who report the appearance of associated symptoms after treatment.",[25,26,27,28],"Chronic Myelocytic Leukemia","Erectile Dysfunctions","CVD - Cardiovascular Disease","Tyrosine Kinase Inhibitor","RECRUITING","2025-08-05",{"date":32,"type":33},"2025-08-06","ACTUAL",{"date":35,"type":33},"2025-07-01",{"date":37,"type":21},"2028-12",{"name":39,"class":40},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":41},"100600031","phase-4-firmonertinib-combined-with-intrathecal-injection-for-the-treatment-of-egfr-mutant-nsclc-with-leptomeningeal-metastases-100600031","NCT07092202","Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases","Exploratory Clinical Study on Dynamic Monitoring of cfDNA in Cerebrospinal Fluid and Peripheral Blood Using High-dose Firmonertinib Combined With Intrathecal Injection of Pemetrexed for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases","Inclusion Criteria:\n\n* Obtain an informed consent form signed by the patient or their legal representative;\n* Age greater than or equal to 18 years old;\n* According to the 9th edition TNM staging of lung cancer by the International Association for the Study of Lung Cancer and the Joint Committee on Cancer Staging in the United States, metastatic (stage IV) NSCLC with histological or cytological confirmation;\n* Confirmed by histological or cytological specimens tested in the central laboratory to have EGFR exon 19 deletion mutation (19DEL) or exon 21 L858R point mutation (L858R), which can exist alone or in combination;\n* ECOG physical condition score is 0-3 points, with an expected life expectancy of ≥ 12 weeks;\n* According to the criteria for evaluating the efficacy of solid tumors (RECIST 1.1), there should be at least one measurable lesion;\n* According to the \"EANO-ESMO\" diagnostic criteria for meningeal metastasis (Type I: positive cerebrospinal fluid cytology or biopsy; Type II: limited to typical clinical symptoms and neuroimaging findings), for clinical judgment. Patients with leptomeningeal metastases who can be included in the study are type I patients and type II patients with EGFR mutations in cerebrospinal fluid ctDNA; merged brain parenchymal metastases can also be included in the study;\n* Progress in first-line treatment with first and second-generation EGFR-TKI;\n* Progress in first-line conventional dose treatment with third-generation EGFR-TKI;\n* The subject must accept and be able to cooperate with the lumbar puncture procedure, and confirm that there are no contraindications to chemotherapy or lumbar puncture;\n* At least 4 weeks before treatment, all extracranial symptoms must be stable, and there must be no CNS complications requiring emergency neurosurgical intervention.\n\nExclusion Criteria:\n\n* Squamous cell carcinoma of the lung;\n* Known history of hypersensitivity reactions to drugs with or without active excipients or similar structures or categories to the investigational drug for famotinib\u002Fpemetrexed;\n* Confirmed EGFR exon 20 insertion mutation;\n* At the beginning of drug treatment, if the toxicity associated with previous anti-tumor therapy has not recovered to ≤ CTCAE Grade 1, except for peripheral neurotoxicity caused by hair loss or chemotherapy ≤ CTCAE Grade 2;\n* Excluding skin basal cell carcinoma, cervical carcinoma in situ, and ductal carcinoma of the breast that have been effectively controlled and have been diagnosed with other malignant tumors or have a history of other malignant tumors in the past 5 years;\n* Patients who are deemed ineligible by researchers to participate in this study, such as those who are highly likely to be unable to comply with the study protocol, constraints, and requirements, or other situations determined by the researcher at their discretion;\n* Pregnancy or lactation.","ALL",{"count":51,"type":21},40,"INTERVENTIONAL",[54],"PHASE4","Leptomeningeal metastases (LM) are a relatively rare site of metastasis in advanced non-small cell lung cancer (NSCLC), and LM patients have a poor prognosis. Numerous retrospective studies have reported that high-dose Firmonertinib can also effectively increase patient prognosis and have tolerable side effects, but there is a lack of prospective studies to confirm this. In addition, there are currently no good biomarkers for monitoring the efficacy of LM treatment. cfDNA testing can be used for early cancer screening, monitoring tumor progression, evaluating treatment response, and discovering drug resistance mechanisms. Due to the influence of the blood-brain barrier, the level of cfDNA in the plasma of LM patients is often very low, and the detection of cfDNA in cerebrospinal fluid (CSF) is more advantageous. Therefore, exploring the dynamic monitoring of LM treatment efficacy using CSF cfDNA is of great significance for improving patient prognosis. Based on this, the applicant intends to conduct a prospective, multicenter, single-arm, post-market exploratory clinical trial on the treatment methods and efficacy monitoring of NSCLC-LM patients. The aim was to explore whether cfDNA has the potential to become a biomarker for LM efficacy monitoring and to validate the efficacy and safety of high-dose fumatinib combined with intrathecal injection in the treatment of NSCLC-LM patients.",[57,58,59,28],"Leptomeningeal Metastasis","NSCLC","Intrathecal Chemotherapy",[61,58,59,62,28,63],"Leptomeningeal metastasis","Firmonertinib","cfDNA","2025-07-27",{"date":66,"type":33},"2025-07-29",{"date":68,"type":33},"2025-04-15",{"date":70,"type":21},"2027-11-01",{"name":72,"class":73},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":52,"phases":83,"briefSummary":85,"conditions":86,"keywords":94,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":41},"100574161","phase-2-neoadjuvant-befotertinib-combined-bevacizumab-or-platinum-based-double-chemotherapy-for-resectable-locally-advanced-egfr-mutation-positive-non-small-cell-lung-cancer-100574161","NCT06755684","Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer","Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer: a Single-center, Randomized Controlled Trial","Inclusion Criteria:\n\n* NSCLC patient with EGFR sensitive mutation as confirmed by needle biopsy;\n* At stage II-IIIA (TNM Staging, Version 8) as identified by chest CT, PET-CT or\u002Fand EBUS;\n* No systemic metastasis (confirmed by head MRI, whole body bone scan, PET-CT, liver and adrenal CT, etc.);\n* With the feasibility to receive radical surgery ;\n* Good lung function that could tolerate surgical treatment;\n* Aged 18-75 years;\n* At least one measurable tumor foci (the longest diameter measured by CT shall be \\> 10 mm);\n* Other major organs shall function well (liver, kidney, blood system, etc.):\n* ECOG PS score shall be 0-1;\n* The child-bearing female must undergo pregnancy test within 7 days before starting the treatment and the result shall be negative. Reliable contraceptive measures, such as intrauterine device, contraceptive pill and condom, shall be adopted during the trial and within 30 days after completion of the trial. The child-bearing male shall use condom for contraception during the trial and within 30 days after completion of the trial;\n* The patient shall sign the Informed Consent Form.\n\nExclusion Criteria:\n\n* The patient has undergone any systemic anti-cancer treatment for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment, etc.;\n* The patient suffers from any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris that starts to attack within the last 3 months, congestive heart failure \\[≥ Grade II specified by New York Heart Association (NYHA)\\], cardiac infarction (6 months before enrollment), severe arrhythmia and liver, kidney or metabolic diseases that requires drug treatment;\n* The patient is a carrier of HIV;\n* The patient has had or is currently suffering from interstitial lung disease;\n* The patient had undergone other major systemic operations or suffered from severe trauma within 3 months before the trial;\n* The patient is allergic to befotertinib or its any excipients;\n* The patient is allergic to bevacizumab or its any excipients;\n* The patient is allergic to platinum-based double chemotherapy or its any excipients;\n* The female patient is in pregnancy or lactation period;\n* There are any conditions under which the investigator considers the patient is not suitable to be enrolled.",{"count":82,"type":21},60,[84],"PHASE2","This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation",[87,88,89,90,91,92,93,28],"EGFR","Non-Small Cell Lung Cancer","Locally Advanced Non-Small Cell Lung Cancer","Pemetrexed","Carboplatin","Bevacizumab","Antineoplastic Agents",[95,58,96,92,97],"EGFR-TKI","Chemotherapy","Locally advanced non-small cell lung cancer","2025-01-03",{"date":100,"type":33},"2025-01-06",{"date":102,"type":33},"2024-11-07",{"date":104,"type":21},"2028-12-31",{"name":106,"class":73},"Peng Zhang",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":52,"phases":116,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":41},"100567030","phase-2-anlotinib-plus-nab-paclitaxels-and-s-1-for-patients-with-advanced-biliary-tract-cancer-as-second-line-treatment-100567030","NCT06662877","Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","Anlotinib Plus Nab-Paclitaxels and S-1 Versus FOLFOX for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment: a Phase 2\u002F3, Multi-centric Double-stage Randomized Controlled Trial","Inclusion Criteria:\n\n1. Signed a written informed consent form before enrollment;\n2. Age \\>18 years, both male and female are eligible;\n3. Patients with pathologically confirmed advanced biliary tract that has progressed after first-line gemcitabine-based therapy;\n4. Have measurable lesions (according to RECIST 1.1 criteria, non-lymph node lesions with a long diameter ≥10 mm on CT scan, or lymph node lesions with a short diameter ≥15 mm on CT scan);\n5. ECOG Performance Status (PS) score: 0-1;\n6. Expected survival time longer than 12 weeks;\n7. Key organ functions meet the following criteria (without the use of any blood components or growth factors within 14 days): Hematology: Neutrophils ≥1.5×10⁹\u002FL; Platelet count ≥100×10⁹\u002FL; Hemoglobin ≥ 90 g\u002FL; Liver and kidney function: Serum creatinine (SCr) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance rate ≥50 ml\u002Fmin (Cockcroft-Gault formula); Total bilirubin (TBIL) ≤ 1.5 times the ULN; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels ≤ 2.5 times the ULN (if abnormal liver function is due to liver metastasis, then ≤ 5 times the ULN); urine protein \\\u003C 2+; if urine protein ≥ 2+, 24-hour urine protein quantification must show protein ≤1g;\n8. Normal coagulation function, no active bleeding or thrombotic diseases: International Normalized Ratio (INR) ≤ 1.5 × ULN; Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN; Prothrombin Time (PT) ≤ 1.5 × ULN;\n9. The subject voluntarily participates in this study, has good compliance, and is willing to cooperate with safety and survival follow-ups.\n\nExclusion Criteria:\n\n1. Subjects with a history of or concurrent malignancies, except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix;\n2. Known allergy to macromolecular protein preparations or known hypersensitivity to the components of the administered drugs;\n3. Subjects with existing thyroid dysfunction that cannot be maintained within the normal range by medication;\n4. Uncontrolled hypertension despite optimal treatment, defined as systolic blood pressure \\>150 mmHg or diastolic blood pressure \\>90 mmHg;\n5. Subjects with uncontrolled cardiac clinical symptoms or diseases, such as: (1) heart failure above NYHA class II, (2) unstable angina, (3) myocardial infarction within the past year, (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n6. Subjects with any active autoimmune disease or a history of autoimmune disease;\n7. Subjects using immunosuppressive agents or systemic or absorbable local corticosteroids for immunosuppressive purposes (prednisone dose \\>10 mg\u002Fday or equivalent efficacy corticosteroids) who continue to use them within 2 weeks before enrollment;\n8. Subjects with central nervous system metastases;\n9. Subjects with active infections or unexplained fever \\>38.5°C during screening or before the first dose (subjects with tumor-related fever, as judged by the investigator, may be enrolled);\n10. Subjects with significant hemoptysis (fresh blood) within 2 months before enrollment or daily hemoptysis volume ≥2.5 ml;\n11. Subjects with any condition that may increase the risk of gastrointestinal bleeding or perforation, such as active peptic ulcers, known intraluminal metastatic lesions, inflammatory bowel disease, history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days before the start of the study;\n12. Subjects with a history or current evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, or severely impaired lung function;\n13. Subjects with a history or current evidence of bronchiectasis, cavitary pulmonary tuberculosis, lung abscess, rheumatic heart disease with mitral valve stenosis, or cardiogenic pulmonary edema, which could cause hemoptysis;\n14. Subjects with congenital or acquired immune deficiencies, such as those infected with HIV or with active hepatitis (transaminase levels not meeting inclusion criteria, hepatitis B reference: HBV DNA ≥1000 IU\u002Fml; hepatitis C reference: HCV RNA ≥1000 IU\u002Fml);\n15. Subjects who have received or may receive a live vaccine within 4 weeks before or during the study;\n16. Subjects with a known history of psychiatric drug abuse, alcoholism, or drug addiction;\n17. Pregnant or breastfeeding women or those planning to conceive during the study period;\n18. Subjects whom the investigator deems should be excluded from the study, such as those with factors that may lead to early termination of the study.",{"count":115,"type":21},206,[84,117],"PHASE3","Biliary tract cancer (BTC) presents with a 5-year survival rate less than 5%. The goal of this clinical trial is to evaluate if Anlotinib plus Nab-Paclitaxels and S-1 as second-line regimen can improve the treatment efficacy in advanced biliary tract cancer (BTC) after progression upon first-line standard treatment, in comparison with standard second-line FOLFOX regimen.",[120,121,96,28],"Biliary Tract Cancer","Second Line Treatment",[123,124,125,126,127,128],"biliary tract cancer","second-line treatment","Nab-Paclitaxels","S-1","Anlotinib","FOLFOX","NOT_YET_RECRUITING","2024-10-27",{"date":132,"type":33},"2024-10-29",{"date":134,"type":21},"2024-11-25",{"date":136,"type":21},"2029-09-01",{"name":138,"class":73},"Sun Yat-sen University",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":52,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":4},"100566726","phase-2-olverembatinib-as-maintenance-therapy-or-preemptive-therapy-after-allo-hsct-in-phall-100566726","NCT06658925","Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL","The Safety and Efficacy of Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Adult Ph + Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* ( 1 ) Acute lymphoblastic leukemia with positive Ph chromosome or BCR \u002F ABL fusion gene ; after allogeneic hematopoietic stem cell transplantation, and survived for more than 30 days after transplantation.\n\n( 2 ) Age older than or equal to 18 years old ( 3 ) Informed consent can be signed by themselves. ( 4 ) Adequate organ function must be met : renal function and liver function are as follows : serum creatinine is 2 times lower than the normal upper limit, AST, ALT and ALP are lower than the normal upper limit of 3 times, and total bilirubin is lower than the normal upper limit of 3 times ( if the liver GVHD is clearly diagnosed, less than or equal to 5 × ULN ) ).\n\n( 5 ) HIV negative, HBV and HCV negative. ( 6 ) The Eastern Oncology Collaborative Group Physical Status Assessment ( ECOG-PS ) was 0-2 points.\n\n( 7 ) Informed consent must be signed before the start of the study procedure, and the informed consent must be signed by the patient himself or his immediate family. Considering the patient 's condition, if the patient 's signature is not conducive to the treatment of the disease, the informed consent is signed by the legal guardian or the patient 's immediate family.\n\nExclusion Criteria:\n\n* ( 1 ) Hematology remission was evaluated at 1 month after transplantation, and complete donor chimerism was achieved.\n\n( 2 ) Severe cardiovascular diseases ( including myocardial infarction, unstable angina pectoris, severe arrhythmia and congestive heart failure, etc. ) occurred during the previous use of the third generations of TKI treatment.\n\n( 3 ) Uncontrolled infection at the time of enrollment ; severe complications of mechanical ventilation or hemodynamic instability ; those who had undergone autologous or allogeneic stem cell transplantation; ( 4 ) The serological reaction of known HIV or active hepatitis C virus is positive ; ( 5 ) suffering from mental illness or other illness and can not cooperate with the research treatment and monitoring requirements ; ( 6 ) being unable or unwilling to sign the consent ; ( 7 ) pregnant or lactating women ; ( 8 ) Patients with other special conditions who were assessed as unqualified by the researchers.",{"count":147,"type":21},50,[84],"This study is a single-center, prospective, single-arm exploratory study. Ph + acute lymphoblastic leukemia patients treated with allogeneic hematopoietic stem cell transplantation were recruited from the Stem Cell Transplantation Center of the Hospital of Hematology, Chinese Academy of Medical Sciences. The number of patients is expected to be 50 cases. The enrolled patients plan to receive Olverembatinib as a post-transplant treatment regimen, including maintenance therapy to prevent recurrence and preemptive treatment. Hematopoietic reconstitution ( neutrophil \\> 0.5 × 10 \\^ 9 \u002F L, platelet \\> 50 × 10 \\^ 9 \u002F L ) was evaluated after enrollment. From 2 months to 3 months after transplantation, Olverembatinib 40 mg QOD was added for maintenance treatment until 2 years after transplantation. During maintenance treatment, Olverembatinib dose ( dose range 20 mg QOD to 40 mg QOD ) can be adjusted according to blood picture, biochemical index or other oral drugs ( triazole drugs, etc. ).",[151,152,28],"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)","HSCT","2024-10-23",{"date":155,"type":33},"2024-10-26",{"date":157,"type":21},"2024-11-01",{"date":159,"type":21},"2027-08-31",{"name":161,"class":73},"Institute of Hematology & Blood Diseases Hospital, China",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":52,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":4},"100557501","phase-2-sbrt-combined-with-adbelimumab-and-apatinib-for-perioperative-and-conversion-therapy-of-hepatocellular-carcinoma-100557501","NCT06538935","SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma","A Phase II, Open-label, Two Arm, Investigator-initiated Trail of Stereotactic Radiotherapy (SBRT) in Combination With an Anti-PD-L1 Inhibitor Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. The patient volunteered to participate in the study and signed an informed consent form\n2. ≥18 years of age，Male or female\n3. Subjects are diagnosed with histologically or cytologically confirmed HCC\n4. Subjects haven't received any systemic treatment for HCC before admission.\n5. Subjects enrolled must have measurable lesion(s) according to the RECIST 1.1 standard\n6. ECOG performance status of 0 or 1\n7. Life expectancy ≥ 12 weeks\n8. Subjects are diagnosed with resectable stage IB- IIIA HCC cancer.\n9. The main organ's function is normal and it should meet the following criteria(Excludes use of any blood components and cell growth factors during the screening period)\n\n   * Absolute neutrophil count≥1.5×109 \u002FL\n   * Platelets≥75×109\u002FL ;Hemoglobin≥9.0 g\u002FdL; Serum albumin≥3g\u002FdL\n   * Thyroid stimulating hormone (TSH)≤1.0×upper limit of normal(ULN)（If abnormal, T3 and T4 levels should be examined at the same time）\n   * Total bilirubin (TBIL)≤1.5×upper limit of normal (ULN); ALT and AST≤1.5×upper limit of normal(ULN); AKP≤ 2.5×upper limit of normal(ULN)\n   * Serum creatinine ≤1.5×ULN or creatinine clearance \\> 60 mL\u002Fminute (using Cockcroft-Gault formula)\n\nExclusion Criteria:\n\n1. Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except HCC within 5 years or simultaneously\n2. Be ready for or previously received organ or allogenic bone marrow transplantation\n3. Moderate-to-severe ascites with clinical symptoms\n4. History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage.\n5. Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment.\n6. Known genetic or acquired hemorrhage or thrombotic tendency.\n7. Thrombosis or thromboembolic event within 6 months prior to the start of study treatment.\n8. Cardiac clinical symptom or disease that is not well controlled.\n9. Subjects have uncontrollable hypertension (systolic pressure ≥ 140 mmHg or diastolic pressure ≥ 90 mmHg), despite patients have taken the best drug treatment ；Subjects have had a hypertensive crisis or hypertensive encephalopathy\n10. Patient develops severe vascular disease within 6 months before the start of study treatment.\n11. Patients with severe, unhealed or split wounds and active ulcers or untreated fractures.\n12. Patients who underwent surgical treatment within 4 weeks prior to the start of study treatment.\n13. Factors to affect oral administration (such as patients unable to swallow oral medications, malabsorption syndrome etc. situations evidently affect drug absorption).\n14. Patients with gastrointestinal diseases such as intestinal obstruction (including incomplete intestinal obstruction) or those who may have caused gastrointestinal bleeding, perforation or obstruction.\n15. There is evidence of intragastric gas that cannot be explained by puncture or recent surgery.\n16. Previous or current presence of metastasis to central nervous system.\n17. Subjects have history of hepatic encephalopathy.\n18. The subject has an interstitial lung disease that is symptomatic or may interfere with the discovery or management of suspected drug-related lung toxicity; previous and current subjects with a history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-associated pneumonia, severe impaired lung function, etc.\n19. The patient has any active autoimmune disease or a history of autoimmune disease expected relapse.\n20. Severe infection within 4 weeks prior to the start of study treatment.\n21. A history of immunodeficiency, including HIV-positive or other acquired, congenital immunodeficiency disease.\n22. The patient is pregnant or breastfeeding.\n23. Subjects were vaccinated with live attenuated vaccine within 28 days before the first dose or expected to receive this vaccine within 60 days after the last dose or during the study period.\n24. Treatment of other investigational product(s) within 28 days prior to the start of study treatment.\n25. Other factors deemed unsuitable for participation in this study by the researchers.",{"count":170,"type":21},80,[84],"This is a Phase II , Open-label , Investigator-initiated Trail of SBRT in Combination With Adbelimumab and Apatinib in Patients With Hepatocellular Carcinoma(HCC).This study aims to evaluate the safety and efficacy of SBRT in Combination With Adbelimumab and Apatinib as a preoperative and conversion treatment of HCC.",[174,175,176,28],"Hepatocellular Carcinoma","SBRT","Immune Checkpoint Blockade","2024-08-05",{"date":179,"type":33},"2024-08-06",{"date":181,"type":21},"2025-01",{"date":183,"type":21},"2027-12",{"name":185,"class":40},"Fujian Cancer Hospital",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":194,"targetDuration":196,"studyType":22,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":41},"100456267","prospective-sampling-in-driver-mutation-pulmonary-oncology-patients-on-tyrosine-kinase-inhibitors-start-tki-100456267","NCT05221372","ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)","proSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors","START-TKI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Able to understand the written informed and able to give informed consent\n* Locally advanced or metastatic NSCLC with oncogenic driver mutation\n* Treatment with TKI according to standard of care\n\nExclusion Criteria:\n\n* Unable to draw blood for study purposes",{"count":195,"type":21},1300,"10 Years","The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.",[199,200,28],"Non Small Cell Lung Cancer","Liquid Biopsy","2022-02-02",{"date":203,"type":33},"2022-02-18",{"date":205,"type":33},"2017-02-02",{"date":207,"type":21},"2031-01-01",{"name":209,"class":73},"Erasmus Medical Center"]